In view of increasing sales demand and to pursue expansion, the Board of Directors of the company decided, in the end of 2002, to set up a new production site: Jiangsu Aosaikang Pharmaceutical Co., Ltd. The construction of the new premises, which occupies 120,000©Owith total investment of 10 million US dollars, is now in full swing. The new factory, located in Jiangning Science Park, Nanjing, is completely designed and programmed in accordance with c-GMP requirement and to be equipped with state-of-art pharmaceutical manufacturing facilities, so as to meet our goal: to serve the society with best quality medical products.

This new production facilities of Aosaikang started production in the early of 2005. As the structural allocation, because of already existing two manufacture sites, it is involved in the manufacture of anti-tumor, cephalosporin and regular freeze dried preparations for injection, oral solid preparations and cephalosropin preparations, which constitutes the platform of R&D and production, so as to achieve the goal of Aosaikang: providing the quality and best medical products for the well being of community.

Jiangsu Aosaikang Pharmaceutical Co., Ltd. is now one of the companies with the greatest variety of anti-tumor pharmaceuticals and proton pump inhibitors in China. In the meantime, it is also one of the largest production bases for proton pump inhibitors and injection. In 2006, it was incorporated into Top 100 private enterprises in Nanjing. In the following year, it was awarded the titles ¡°Hi-tech Enterprise in Jiangsu Province¡±, ¡°Hi-tech Enterprise in Nanjing¡±, ¡°National Private Scientific and Technological Enterprise¡±, ¡°Private Scientific and Technological Enterprise in Jiangsu Province¡± and ¡°Outstanding Private Enterprise in Nanjing¡±. In the same year, it passed the examination of the program Top 100 Growing Scientific and Technological Enterprises in Nanjing.